

DAFTAR PUSTAKA

1. Rowley JD. The critical role of chromosome translocations in human leukemias. *Annu Rev Genet.* 1998;32:495–519.
2. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. *Nat Rev Cancer.* 2006;6(3):193–203.
3. American Cancer Society. About Acute Myeloid Leukemia (AML). *Am Cancer Soc.* 2018;
4. Kemenkes RI. Profil Kesehatan Indonesia Tahun 2014. Jakarta Kemenkes RI. 2015;
5. Jackson SP. The growing complexity of platelet aggregation. *Blood.* 2007;109(12):5087–95.
6. DeSancho MT, Rand JH. Bleeding and thrombotic complications in critically ill patients with cancer. *Crit Care Clin.* 2001;17(3):599–622.
7. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. *Br J Haematol.* 2009;145(1):24–33.
8. Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: Who needs them? *Br J Haematol.* 2011;154(4):425–40.
9. Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, *et al.* Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update. *J Clin Oncol.* 2018;36(3):283–99.
10. Rebulli P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, *et al.* The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. *N Engl J Med.* 1997 Dec;337(26):1870–5.
11. Kubler A, Mayr F, Baldinger K, Al E. Platelet transfusion for the treatment of bleeding complications in patients with hematological malignancies: a retrospective cohort study. *Med.* 2018;97(35):e12154.
12. Patel A, Patel J, Patel M. Efficacy of platelet transfusion in acute leukemia patients: A systematic review and meta-analysis. *J Clin Oncol Res.* 2018;1(1):1–8.
13. Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, *et al.* A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. *N Engl J Med.* 2013;368(19):1771–80.
14. Petraszko T, Zeller M. Platelet Transfusion, Alloimmunization and

Management of Platelet Refractoriness. Clin Guid to Transfus. 2018;Chapter 18:1–18.

15. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness - practical approaches and ongoing dilemmas in patient management. *Br J Haematol.* 2015 Nov;171(3):297–305.
16. Holbro A, Infanti L, Sigle J, Buser A. Platelet transfusion: Basic aspects. *Swiss Med Wkly.* 2013;143:1–10.
17. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. *Harrison's principles of internal medicine.* 20th ed. McGraw Hill Professional; 2018.
18. The Leukemia & Lymphoma Society. Risk Factors for Leukemia. 2021;
19. American Cancer Society. Acute Myeloid Leukemia Causes, Risk Factors, and Prevention. *Am Cancer Soc.* 2018;1–10.
20. Schwab C, Harrison CJ. Acute lymphoblastic leukaemia. *Methods Mol Biol.* 2011;730:99–117.
21. Johansson B, Harrison CJ. Acute Myeloid Leukemia. *Cancer Cytogenet.* 2010;45–139.
22. Permono B. *Buku Ajar Hematologi-Onkologi Anak.* IDAI. Jakarta; 2010.
23. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, *et al.* Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. *Blood.* 2002;99(10):3547–53.
24. Gökbüget N, Hoelzer D. Treatment of Adult Acute Lymphoblastic Leukemia. *Semin Hematol.* 2009;46(1):64–75.
25. Topp MS, Gökbüget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, *et al.* Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. *Lancet Oncol.* 2015 Jan;16(1):57–66.
26. Calistania C, Mulansari N. Purpura Trombositopenia Idiopatik. In: Tanto C, Liwang F, Hanifati S, *et al*, *Kapita Selektta Kedokteran.* 4th ed. Jakarta: ECG; 2014. p. 668–9.
27. Jeremy W, Roger L. Platelets and Haemostasis. In: Jeremy W dan Roger L, *Physiology at a Glance.* 4th ed. USA: Wiley Blackwell; 2017. p. 46–9.
28. Barrett KE, Barman SM, Boitano S, Brooks HL. Local and Humoral Control of Tissue Blood Flow. In: Barrett KE, Barman SM, Boitano S, Brooks HL, *Ganong's Review of Medical Physiology.* 25th ed. United State: McGraw Hill Professional; 2016.

29. L S. Darah. In: Sherwood L, Fisiologi Manusia dari Sel ke Sistem. 8th ed. Jakarta: ECG; 2016. p. 421–46.
30. Tanzil A. Hemostasis dan Pembeuan Darah. In: Guyton dan Hall, Buku Ajar Fisiologi Kedokteran. 12th ed. Jakarta: Saunders Elsevier; 2014. p. 451–60.
31. Booth C, Allard S. Blood transfusion. *Medicine (Baltimore)*. 2017 Apr 1;45(4):244–50.
32. Gernsheimer T, Slichter S. Preservation and Clinical Use of Platelets. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, *et al.*, editors. *Williams Hematology*, 9e. New York, NY: McGraw-Hill Education; 2016.
33. Wang Q, Yang J, Stevens L, Wang D. Research Progress of Platelet Transfusion in China. *Transfus Med Rev*. 2017 Apr 1;31(2):113–7.
34. Cardigan R, Williamson LM. The quality of platelets after storage for 7 days. *Transfus Med*. 2003;13(4):173–87.
35. Dumont LJ, Dumont DF, Unger ZM, Siegel A, Szczepiorkowski ZM, Corson JS, *et al.* A randomized controlled trial comparing autologous radiolabeled in vivo platelet (PLT) recoveries and survivals of 7-day-stored PLT-rich plasma and buffy coat PLTs from the same subjects. *Transfusion*. 2011;51(6):1241–8.
36. Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ. *Williams Hematology*. 9th ed. New York: McGraw-Hill Education; 2016. 541–558 p.
37. Ness P, Braine H, King K, Barrasso C, Kickler T, Fuller A, *et al.* Single-donor platelets reduce the risk of septic platelet transfusion reactions. *Transfusion*. 2001;41(7):857–61.
38. Heddle NM, Cook RJ, Blajchman MA, Barty RL, Sigouin CS, Boye DM, *et al.* Assessing the effectiveness of whole blood–derived platelets stored as a pool: a randomized block noninferiority trial. *Transfusion*. 2005;45(6):896–903.
39. Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ. Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review. *Transfusion* [Internet]. 2008;48(7):1447–58. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1537-2995.2008.01731.x>
40. Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, *et al.* Platelet Transfusion: A Clinical Practice Guideline From the AABB. *Ann Intern Med*. 2015 Feb 3;162(3):205–13.
41. Haroen H. Darah dan Komponen: Komposisi, Indikasi dan Cara

- Pemberian. In: Sudoyo A, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. *Buku Ajar Ilmu Penyakit Dalam* jilid II. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI; 2006. p. 675–80.
42. Zeidler K, Arn K, Senn O, Schanz U, Stussi G. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. *Transfusion*. 2011 Nov 1;51(11):2269–76.
 43. Haas B, Chittams JL, Trerotola SO. Large-bore Tunneled Central Venous Catheter Insertion in Patients with Coagulopathy. *J Vasc Interv Radiol*. 2010 Feb 1;21(2):212–7.
 44. Howard SC, Gajjar A, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, *et al*. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. *J Am Med Assoc*. 2000;284(17):2222–4.
 45. Vavricka SR, Walter RB, Irani S, Halter J, Schanz U. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. *Ann Hematol*. 2003;82(9):570–3.
 46. Haas FJ, van Rhenen DJ, de Vries RR, Others. National users' board Sanquin blood supply. *Blood Transfus Guidel*. 2011;
 47. Szczepiorkowski ZM, Dunbar NM. Transfusion guidelines: when to transfuse. *Hematology Am Soc Hematol Educ Program*. 2013;638–44.
 48. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, *et al*. PROPPR Study Group: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 versus a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA*. 2015;313:471–82.
 49. Jaime-Pérez JC, Vázquez-Hernández KE, Jiménez-Castillo RA, Fernández LT, Salazar-Riojas R, Gómez-Almaguer D. Platelet survival in hematology patients assessed by the corrected count increment and other formulas. *Am J Clin Pathol*. 2018;150(3):267–72.
 50. Zeller M. Chapter 18: Platelet transfusion, alloimmunization and management of platelet refractoriness. In: *Services CB Clinical Guide to Transfusion*. Canada: Canadian Blood Services; 2016. p. 1–14.
 51. Thuku NW, Shikuku K, Mbugua A. Determination in vivo viability of a transfused platelet product by corrected count increment and percentage platelet response. *Pan Afr Med J*. 2017;27:1–7.
 52. Hagino T, Sato T, Tsuno NH, Tasaki T. Incidence and management of non-immune platelet transfusion refractoriness: A narrative review. *Ann Blood*. 2021;6(May).
 53. Neanaey WA, Deghady AA, Nafea DA, Fahmy NM, Gouda AM. Evaluation of Human Leucocyte Antigen Mediated Platelet Transfusion Refractoriness and Platelet Crossmatching Assay in Patients with

Hematologic Disorders. *Oman Med J.* 2022;37(4):40.

54. Khelfa M, Leclerc M, Kerbrat S, Boudjemai YNS, Benchouaia M, Neyrinck-Leglantier D, *et al.* Divergent CD4+ T-cell profiles are associated with anti-HLA alloimmunization status in platelet-transfused AML patients. *Front Immunol.* 2023;14(August):1–13.
55. Basak SK, Iktidar MA, Chowdhury R, Khatun A, Rahman A, Miah SS, *et al.* Response to apheretic platelet transfusion in children of acute lymphoblastic leukemia receiving induction chemotherapy: a cross-sectional study from Bangladesh. *Ann Med Surg.* 2024;86(3):1346–51.
56. Rahman SR, Jamal CY, Khasru AAM, Khan ZJ, Akter M, Ara Z, *et al.* Influence of Nutritional Status of Children with Acute Lymphoblastic Leukemia (ALL) on Treatment Outcome after Completion of Induction. *Bangladesh J Child Heal.* 2023;46(1):3–8.
57. Rafika R, Amelia D, Naim N, Hasan ZA. Perbandingan Kualitas Trombocyte Concentrate Dari Platelet Rich Plasma Dan Platelet Apheresis Pada Jumlah Trombosit Dan Residu Leukosit. In 2021.
58. Anggini R, Sepvianti W, Wulandari M. Gambaran Jumlah Trombosit Pada Sediaan Darah Thrombocyte Concentrate (TC) Selama Masa Simpan 5 Hari. In 2019.
59. Maharani EA, Astuti D. Analisis Kontrol Kualitas Komponen Trombosit : Studi Perbandingan Metode Pembuatan Komponen Trombosit. *J Indones Med Lab Sci.* 2022;3(2):158–69.
60. Astuti D, Maharani EA. Identifikasi Bakteri yang Mengontaminasi Konsentrat Trombosit. In 2014.
61. Santril NR. Gambaran Efektivitas Transfusi Thrombocyte Concentrate Pada Pasien Immune Thrombocytopenic Purpura di RSUP Dr. M. Djamil Padang. *Maj Kedokt Andalas.* 2024;46(9):1440–6.
62. Nancy YM. Perbedaan Kebutuhan Transfusi Darah Selama Fase Induksi pada Leukemia Limfoblastik Akut. *Sari Pediatr.* 2016;13(4):271.
63. Pasala M, Ihsan M, Ikawati Z. Faktor yang Memengaruhi Luaran Klinik Kemoterapi dengan Protokol Tahun 2013 pada Anak dengan Leukemia Limfoblastik Akut. *Maj Farm.* 2021;17(1):106.
64. Fitriani SW, Mutiara R, Malik A, Andriastuti M. Angka Kejadian dan Faktor yang Memengaruhi Potensi Interaksi Obat dengan Obat pada Pasien Leukemia Akut Anak yang Menjalani Rawat Inap. *Sari Pediatr.* 2016;18(2):129.
65. Falah A, Widiretnani S, Umma HA. Pengaruh Toksisitas Hematologi Fase Konsolidasi Terhadap Kesintasan Pasien Leukemia Limfoblastik Akut di Rumah Sakit Umum Daerah Dr. Moewardi Surakarta. *Sari Pediatr.*

2023;24(5):327.

66. Andriastuti M, Chozie NA, Rahmani S. Efektivitas Transfusi Trombosit Hasil Uji Silang Serasi (Crossmatch) pada Kondisi Trombositopenia Refrakter. *Sari Pediatr.* 2018;20(1).
67. Annisa Ahla; Ahmad Muhlisin; Neni Oktiyani; Erfan Roebiakto, S.KM. M. Gambaran Trombosit Pada Pasien Leukemia Akut di Rumah Sakit Umum Daerah Ulin Banjarmasin. 2021;
68. Febriansyah M. Gambaran Jumlah Trombosit Pada Penderita Leukemia di Rsup Dr. Mohammad Hoesin Palembang Tahun 2018. 2018;
69. Wairo CM, Nugroho S, Suyuti H. Peran Ekspresi P53 dan Survivin Terhadap Hemoglobin, Leukosit, dan Trombosit Pada Leukemia Limfoblastik Akut Anak yang Mendapatkan Kemoterapi. *Maj Kesehat.* 2019 Mar 1;6(1):23–34.
70. Hariani E. Hubungan Jumlah Trombosit dan Neutrofil dengan Gambaran Kelainan Kulit pada Pasien Leukemia Limfositik Akut (LLA) dan Leukemia Mielositik Akut (LMA) Anak. In 2018.
71. Syafitri R, Shoumi D. Perbedaan Kadar Trombosit Pada Pasien Trombositopenia Sebelum dan Sesudah Transfusi Trombosit Konsentrat di RSUD Karawang Tahun 2019 – 2020. *Ensiklopedia J.* 2022 Mar 22;4(3):107–13.
72. Rahmadin B, Wahid I, Yaswir R. Profil Penderita Leukemia Mieloblastik Akut di Bagian Penyakit Dalam RSUP Dr. M. Djamil Padang. *J Kesehat Andalas.* 2018;6(3):495.
73. Pertiwi N. M. I, R N, K A. Gangguan Hematologi Akibat Kemoterapi Pada Anak Dengan Leukemia Limfositik Akut Di Rumah Sakit Umum Sanglah. *Farm Udayana.* 2013;2(3):59–62.
74. Ratnaningsih T, Widyantara AB. Acute Megakaryoblastic Leukemia (Aml-M7) in 10-Month-Old Baby Boy With Down Syndrome. *Biomedika.* 2022;14(1):90–8.
75. De Kruijff E, Van Gammeren AJ, Porcelijn L, Van Esser JWJ. Post-transfusion purpura in a woman with acute myeloid leukemia. *Neth J Med.* 2019;77(2):81–3.
76. Lubis AM, Sudoyo AW, Effendy S, Djumhana T, Harimurti K. Hubungan Antibodi Anti Trombosit terhadap Respon Transfusi Trombosit pada Pasien Hemato- Onkologi yang Mendapatkan Multitransfusi Trombosit di RS Dr. Cipto Mangunkusumo. *J Penyakit Dalam Indones.* 2017;2(4):200.
77. Meika M D, Triyono T, Sianipar O. Kesesuaian Antara Percentage Platelet Recovery dan Corected Count Increment dalam Menilai Keberhasilan Transfusi Tromboferesis Pada Pasien Keganasan Hematologi. 2022;

78. Tu S-K, Fan H-J, Shi Z-W, Li X-L, Li M, Song K. First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report. *World J Clin Cases*. 2023;11(29):7156–61.
79. Li Y, Song Z, Sun X, Tang J, Zhou X. Changes in inflammatory responses and autophagy during apheresis platelet preservation and their correlation with platelet transfusion refractoriness in patients with acute lymphoblastic leukemia. *Biomol Biomed*. 2023;23(6):956–67.
80. Hosea MK, Andarsini MR, Ugrasena IDG, Wardhani ANK, Cahyadi A, Larasati MCS. Risk factors of platelet refractoriness after thrombocyte concentrate transfusion in pediatric acute leukemia. *Int J Health Sci (Qassim)*. 2022;6(July):866–76.
81. Ladaïque P, Etienne JM, Pedini P, Chiaroni J, Vey N, Picard C, *et al*. Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPT™ Blood System) in acute myeloid leukemia patients undergoing chemotherapy with curative intent: A single center experience. *Blood Transfus*. 2023;21(5):400–8.

